Write a review
Reviews: 0
Manufacturers: Laboratoires Fournier SA
Active ingredients
- Not indicated. See instructions
Disease class
- Prostatic hyperplasia
Clinical and pharmacological group
- Not indicated. See instructions
Pharmacological action
- Antiproliferative
Pharmacological group
- Agents affecting metabolism in the prostate gland and urodynamic correctors
Pharmacological properties of the drug Tadenan
Pharmacodynamics. African plum bark extract suppresses the proliferation of prostate fibroblasts stimulated by b-FGF (the main fibroblast growth factor), which has recently been assigned a significant role in the etiology and pathogenesis of prostate adenoma, since it has been established that prostate cells proliferate only in the presence of a growth factor . By inhibiting the proliferation of fibroblasts, African plum extract suppresses the proliferation of conjoined tissue in the prostate gland and prevents fibrosis. In addition, it should be noted that African plum extract does not affect the activity of hormones in the male reproductive system. Pharmacokinetics . Not studied.
Tadenan capsule
Instructions for medical use of the drug
Description of pharmacological action
A herbal preparation for the treatment of benign prostatic hyperplasia. Reduces proliferation of prostate cells. Has anti-inflammatory and anti-edema effects. The action is determined by the antiproliferative effect on fibroblasts stimulated by b-FGF (the main fibroblast growth factor). Eliminates and reduces functional urination disorders - dysuria, nocturia, pollakiuria in diseases of the prostate gland. Reduces the inflammatory reaction in the tissues of the prostate gland and enhances its secretory activity; reduces the amount of residual tissue after surgery.
Indications for use
Urinary disorders due to benign prostatic hyperplasia (adenoma).
Release form
capsules 50 mg; contour packaging 10, cardboard pack 1; capsules 50 mg; contour packaging 10, cardboard pack 3; capsules 50 mg; contour packaging 10, cardboard pack 2; capsules 50 mg; contour packaging 30, cardboard pack 1; capsules 50 mg; contour packaging 30, cardboard pack 2;
Pharmacodynamics
It has an antiproliferative effect on fibroblasts stimulated by b-FGF (the main fibroblast growth factors), which currently play a significant role in the etiology and pathogenesis of prostate adenoma. Does not affect hormonal levels.
Pharmacokinetics
Data on the pharmacokinetics of the drug Tadenan are not provided.
Use during pregnancy
Tadenan is not intended for women.
Contraindications for use
Hypersensitivity to the drug.
Side effects
From the gastrointestinal tract: rarely - nausea, constipation or diarrhea. Rarely - allergic reactions.
Directions for use and doses
Orally, before meals, 50 mg 2 times a day (morning and evening). The course of treatment is 6–8 weeks; If necessary, it is possible to conduct repeated courses.
Overdose
Currently, there are no data on overdose of the drug Tadenan.
Interactions with other drugs
Currently, there is no data on drug interactions with Tadenan.
Precautions for use
Benign prostatic hyperplasia requires regular monitoring of the prostate gland, including periodic digital rectal examination to rule out prostate cancer. Due to the fact that the drug contains peanut oil, there is a risk of hypersensitivity reactions.
Special instructions for use
During treatment, systematic monitoring of the condition of the prostate gland is necessary. Tadenan therapy cannot replace necessary surgical intervention.
Storage conditions
At a temperature not exceeding 25 °C.
Best before date
36 months
ATX classification:
G Genitourinary system and sex hormones
G04 Preparations for the treatment of urological diseases
G04C Preparations for the treatment of benign prostatic hyperplasia
G04CX Other drugs for the treatment of benign prostatic hyperplasia
G04CX01 Pygeum africanum
Special instructions for the use of the drug Tadenan
During treatment, systematic monitoring of the condition of the prostate gland is necessary. Therapy with Tadenan does not replace surgical intervention, if necessary. Monitoring the condition of the prostate gland should include regular rectal examination to detect prostate cancer. When treating patients with a history of allergic reactions, it is necessary to take into account the presence of peanut oil in the drug. The drug is not intended for the treatment of women. There is no data on the negative effect of Tadenan on the ability to drive vehicles.
Similar drugs:
- Leflunomide Oral tablets
- Permixon Capsule
- Genferon Rectal suppositories
- Genferone Light Nasal Spray
- Beloderm Cream for external use
- Alfaferone Solution for injection
- Leflunomide Substance-powder
- Adenostop Concentrate for the preparation of solution for oral administration
- Altevir Solution for injection
- Beloderm Ointment for external use
** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use the drug Tadenan, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.
Are you interested in the drug Tadenan? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.
** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Tadenan is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!
If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.
Tadenan®
Manufacturer: Laboratoires FOURNIER SA (France)
◊ caps. 50 mg: 10, 20, 30 or 60 pcs. Reg. No.: P N014669/01
Clinical and pharmacological group:
Herbal medicine used for functional urination disorders associated with benign prostatic hyperplasia
Release form, composition and packaging
◊ Capsules
soft gelatin, size No. 4, oval, consisting of two longitudinal halves of opaque white/light green color; the contents of the capsules are a brown oily liquid.
| 1 caps. | |
| African plum bark extract | 50 mg |
Excipients:
peanut oil (150 mg).
Composition of the capsule shell:
gelatin, glycerol, titanium dioxide, copper-sodium chlorophyllin.
10 pieces. - blisters (1) - cardboard packs. 10 pieces. - blisters (2) - cardboard packs. 10 pieces. - blisters (3) - cardboard packs. 30 pcs. - blisters (1) - cardboard packs. 30 pcs. - blisters (2) - cardboard packs.
Description of the active components of the drug "Tadenan®"
pharmachologic effect
A herbal preparation for the treatment of benign prostatic hyperplasia. Reduces proliferation of prostate cells. Has anti-inflammatory and anti-edema effects. The action is determined by the antiproliferative effect on fibroblasts stimulated by b-FGF (the main fibroblast growth factor). Eliminates and reduces functional urination disorders - dysuria, nocturia, pollakiuria in diseases of the prostate gland. Reduces the inflammatory reaction in the tissues of the prostate gland and enhances its secretory activity; reduces the amount of residual tissue after surgery.
Indications
- treatment of moderate functional disorders of the urinary system with benign prostatic hyperplasia (adenoma) (frequent urination during the day and at night, weak stream pressure, intermittent urination, a feeling of incomplete emptying of the bladder, urgency and urination);
— condition after adenomectomy and prostatectomy.
Dosage regimen
The drug is prescribed orally at 50 mg (1 capsule) 2 times a day in the morning and evening or 100 mg (2 capsules) 1 time a day, preferably before meals. Daily dose – 100 mg. The course of treatment averages 6 weeks and can be extended to 8 weeks. If necessary, a repeat course of treatment is possible.
Side effect
From the digestive system:
rarely - constipation, nausea, loss of appetite, constipation, diarrhea.
From the reproductive system:
very rarely - gynecomastia, pain in the testicles.
Allergic reactions:
rarely - urticaria.
Contraindications
- hypersensitivity to the drug.
Pregnancy and lactation
Tadenan is not intended for women.
special instructions
Benign prostatic hyperplasia requires regular monitoring of the prostate gland, including periodic digital rectal examination to rule out prostate cancer.
Therapy with Tadenan does not replace surgery, if necessary.
Due to the fact that the drug contains peanut oil, there is a risk of hypersensitivity reactions.
Overdose
Currently, there are no data on overdose of the drug Tadenan.
Drug interactions
Currently, there is no data on drug interactions with Tadenan.
Conditions for dispensing from pharmacies
The drug is approved for use as a means of OTC.
Storage conditions and periods
The drug should be stored out of the reach of children at a temperature not exceeding 25°C. Shelf life – 3 years.
Drug interactions
Currently, there is no data on drug interactions with Tadenan.
special instructions
Individuals with a peanut butter allergy are at increased risk of allergic reactions, including severe anaphylactic reactions, when using Tadenane.
During treatment with the drug, taking into account the risk factors and health status of the patient, routine medical supervision and examination of the prostate are required.
Taking Tadenan does not replace surgical intervention in cases where it is necessary.
There are no data on the use of the drug in patients with hepatic or renal insufficiency.
The effect of the drug on the ability to drive vehicles and other machinery is unknown, since such studies have not been conducted.
Release form and composition
Tadenan is available in the form of soft gelatin capsules, oval in shape and consisting of two longitudinal halves of an opaque white/light green color; capsules are size No. 4; contents – oily brown liquid (10 pcs each in blisters made of polyvinyl chloride and aluminum foil, 1, 2 or 3 blisters in a cardboard package; 30 pcs each in blisters made of polyvinyl chloride and aluminum foil, 1 or 2 blisters in a cardboard package).
Composition per 1 capsule:
- active ingredient: thick extract of African plum bark (Pygeum africanum Hook) – 50 mg;
- auxiliary component: peanut oil – 150 mg;
- capsule shell: titanium dioxide, gelatin, glycerol, copper sodium chlorophyllin.
